Vertaling van "oral contraceptives cohort data from " (Nederlands → Frans) :

(Hannaford 2007) Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College
(Hannaford 2007) Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from

Bespreking van: Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large US cohort comparing
2011; 10(9):108-9. Analyse de Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large

(Dinger 2011) Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large US cohort comparing
(Dinger 2011) Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large US cohort

compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ
drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States

(Dinger 2007) Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the
(Dinger 2007) Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral

(Hannaford 2010) Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: cohort evidence from Royal College
(Hannaford 2010) Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: cohort evidence from

FTY720 (fingolimod), a novel oral development therapy for multiple sclerosis, showed superior efficacy compared to interferon beta-1a (Avonex ® ) in preliminary data from the Phase III TRANSFORMS study made public in December.
FTY720 (fingolimod), nouveau traitement par voie orale de la sclérose en plaques (SP), a démontré une efficacité supérieure à celle de l’interféron bêta-1a (Avonex ® ) dans des résultats préliminaires provenant de l’étude de phase III TRANSFORMS et publiés en décembre.

FTY720 (fingolimod), a novel oral development therapy for multiple sclerosis, showed continued low relapse rates after four years in patients with relapsing-remitting MS in an open-label Phase II extension study. The data, presented at the American Academy of Neurology (AAN) meeting in April, also showed no significant change in the safety profile from three to four years.
FTY720 (fingolimode), nouveau traitement par voie orale de la sclérose en plaques (SEP), a continué de montrer de faibles taux de rechute après quatre ans de traitement de patients souffrant de la forme cyclique (poussées/rémissions) de la SEP, selon les résultats d’un essai ouvert étendu de phase II. Les résultats présentés au congrès de l’American Academy of Neurology, qui a eu lieu en avril, ont également montré que le profil d’innocuité n’avait pas changé en passant de trois à quatre ans.